What is the global market size of 3D Bioprinting Market?

Global 3D Bioprinting Market size was valued at USD 1.08 billion in 2021 and is poised to grow from USD 1.3 billion in 2022 to USD 5.92 billion by 2030, growing at a CAGR of 20.8% in the forecast period (2023-2030).

Who are the key vendors in the Global 3D Bioprinting Market?

The market's leading players are focusing on providing advanced and innovative solutions to meet the growing needs of industries. These prominent firms are investing in research and development to create novel services and materials and are highly focused in forming strategic alliances and collaborating to develop next-generation solutions. For instance, in February 2022, Imaginarium collaborated with Ultimaker to launch a desktop and industrial 3D printer range in India. This collaboration will assist Ultimaker in expanding its business in India, where additive manufacturing is expected to reach a tipping point in the coming years. 'EnvisionTEC, Inc.', 'Organovo Holdings, Inc.', ' 3D Systems, Inc. ', ' CELLINK AB ', ' Stratasys Ltd. ', ' Allevi, Inc. ', ' Rokit Healthcare ', ' Poietis SAS ', ' Aspect Biosystems Ltd. ', ' Cyfuse Biomedical K.K. ', ' Biobots, Inc. ', ' Advanced Solutions, Inc. ', ' regenHU Ltd. ', ' Volumetric, Inc. ', ' Materialise NV ', ' BioBots ', ' Microdrop Technologies GmbH ', ' GeSiM mbH ', ' Luxexcel Group BV ', ' 3D Biotek, LLC ', 'In December 2022, The National Eye Institute (NEI), which is part of the National Institutes of Health, printed a mixture of cells that constitute the outer blood-retina barrier—eye tissue that supports the retina's light-sensing photoreceptors. The approach allows researchers to examine degenerative retinal illnesses such as age-related macular degeneration with a theoretically infinite supply of patient-derived tissue (AMD).'

What is the key driver of Global 3D Bioprinting Market?

Several pharmaceutical companies are rapidly implementing 3D bioprinting products and technology in the process of discovering and developing novel medications. In comparison to the traditional drug testing technique, 3D bioprinting enables the pharmaceutical sector to test drugs more affordably and safely. The 3D bioprinting process allows pharmaceutical companies to test a medicine in a matter of hours, cutting the three to six years it traditionally takes to develop a new drug. Using 3D bioprinted tissues, R&D teams can test new treatments early on as well as during preclinical investigations. Reduced animal testing, increased productivity, and a more rapid medication development process are all advantages of 3D bioprinting. Furthermore, the growing utilization of 3d printing in cosmetic industry is driving the market growth. The European Commission has banned animal testing for cosmetics since March 2013. As a result, some cosmetics and healthcare companies have used 3D bioprinting to develop cutting-edge 3D tissue models and drug screening methodologies.

What is the key market trend for Global 3D Bioprinting Market?

The rising usage of 3D bioprinting in advanced dermatology is a major trend observed in the market. Burns and scars, particularly on exposed regions of the body, can have a negative impact on an individual's look. The increased consumer awareness of personal appearance is driving an increase in the number of dermal surgeries and treatments throughout the world. According to the National Institute of Aging in the United States, a significant proportion of the population between the ages of 16 and 33 is adopting advanced dermatology. This is generating enough traction for goods manufacturers. Growing self-care awareness is one of the primary factors driving the growth of the 3D bioprinting market in developed regions. Furthermore, 3D bioprinting in healthcare aids in skin tissue bioprinting.

Which region accounted for the largest share in Global 3D Bioprinting Market?

North America region dominated the 3D Bioprinting market in 2021 and is expected to maintain its dominance throughout the forecast period, owing to increased spending on innovative manufacturing technologies by industrialized countries such as Canada and the United States. Moreover, numerous government agencies, such as the National Aeronautics and Space Administration (NASA), have identified significant R&D investments that can significantly contribute to space applications and produce new technologies that fuel commercial growth.

3D Bioprinting Market Size, Share, Growth Analysis, By Component(3D Bioprinters and Bioinks), By Material(Living Cell and Hydrogel), By Technology(Inkjet-based and Magnetic Levitation), By Region - Industry Forecast 2024-2031

Report ID: SQMIG20I2072 | Region: Global | Published Date: August, 2024
Pages: 157 | Tables: 150 | Figures: 81

3D Bioprinting Market Insights

Global 3D Bioprinting Market size was valued at USD 1.08 Billion in 2022 and is poised to grow from USD 1.3 Billion in 2023 to USD 5.92 Billion by 2031, growing at a CAGR of 20.8% in the forecast period (2024-2031).

Primary drivers of this market expansion include the aging population with chronic respiratory disorders and the scarcity of organ donors. Rising R&D spending, technological advancement, and the rise in the prevalence of chronic illnesses are all expected to drive market expansion over the course of the forecast period. The ability of technology to create complex solid organs such as hearts, kidneys, and lungs for transplantation is driving the growing importance of 3D printing in the medical sector. Moreover, 3D bioprinting technology makes it easier to create customized organ and tissue architectures according to a patient's requirements, allowing for more specialized medical procedures and transplants. They solve the organ shortage and provide better approaches in cases of complicated diseases. For this and many other reasons, with the increasing demand in healthcare for personalized patient treatment, it's a driving force for high-performance bioprinters.

3D Bioprinting Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market is highly heterogeneous in nature and has constantly undergone rapid changes. This is a very highly technology-driven and competitive market that decides the company behavior. Large companies have been encouraging the growth of the bioprinting market by their strategic collaborations, product portfolio expansion, and development of improved bioprinting technologies. Some of the large companies in the market are 3D Systems Corporation, Organovo Holdings Inc., BICO Group AB, and Merck KGaA. Certain key contemporary tendencies influencing the sector include high-resolution bioprinting techniques, entry into the market by emerging economies, and attempts to navigate complex regulatory regimes. 'Merck KGaA ', 'Poietis SAS ', 'Allevi, Inc. ', 'BICO Group AB ', 'Tissuelabs ', 'Materialise NV ', '3D Biotek, LLC ', 'Microdrop Technologies GmbH ', 'REGEMAT 3D, SL ', 'MEDPRIN ', 'PRODWAYS ', 'Stratasys Ltd. ', 'Organovo Holdings, Inc. ', 'CELLINK AB ', 'Tissuelabs '

Many pharmaceutical companies are finding and developing novel pharmaceuticals rapidly by utilizing 3D bioprinting products and technology. 3D printing of tissues is more secure and reasonably priced in drug testing in the pharmaceutical business compared to the traditional approach. Due to this 3D bioprinting technology, testing of a medicine may be done by pharmaceutical companies within a few hours instead of the three to six years it takes to manufacture a new one. With the support of 3D bioprinted tissues, R&D teams may perform early and preclinical testing of candidate drugs. Other major advantages of three-dimensional bioprinting include reduction of animal testing, more production, and faster development of drugs.

More alliances formed among research organizations, biotechnology companies, and university institutions fasten the pace of development for 3D bioprinting technologies. This leads to exchanges in knowledge and resources, producing breakthroughs that drive growth in the market.

North America holds a leading position in the 3D bioprinting market over the forecast period. It is anticipated that the healthcare industry's increasing reliance on IT will lead to growth. Furthermore, developed countries such as the US and Canada are allocating more funds for advanced manufacturing technology. Furthermore, several governmental agencies, such as the National Aeronautics and Space Administration (NASA), have realized the importance of allocating substantial resources to research and development (R&D) to significantly progress space applications and produce innovative technologies that promote economic growth.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

3D Bioprinting Market Size, Share, Growth Analysis, By Component(3D Bioprinters and Bioinks), By Material(Living Cell and Hydrogel), By Technology(Inkjet-based and Magnetic Levitation), By Region - Industry Forecast 2024-2031

3D Bioprinting Market Insights

3D Bioprinting Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of 3D Bioprinting Market?

Who are the key vendors in the 3D Bioprinting Market?

What is the key driver of 3D Bioprinting Market?

What is the key market trend for 3D Bioprinting Market?

Which region accounted for the largest share in 3D Bioprinting Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300